Drug Shortage Report for ROPIVACAINE HYDROCHLORIDE INJECTION, USP

Last updated on 2025-02-08 History
Report ID 243515
Drug Identification Number 02439379
Brand name ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Common or Proper name ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) ROPIVACAINE HYDROCHLORIDE
Strength(s) 2MG
Dosage form(s) SOLUTION
Route of administration EPIDURAL INFILTRATION INFILTRATION EPIDURAL
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 200 mL
ATC code N01BB
ATC description ANESTHETICS, LOCAL
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2024-12-04
Estimated end date 2025-02-10
Actual end date 2025-02-07
Shortage status Resolved
Updated date 2025-02-08
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Ropivacaine Hydrochloride Injection, USP 2 mg/mL freeflex® Bag 200 mL effective December 4, 2024, until February 10, 2025.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2025-02-08 English Compare
v5 2025-02-07 French Compare
v4 2025-02-07 English Compare
v3 2024-12-05 English Compare
v2 2024-11-21 French Compare
v1 2024-11-21 English Compare

Showing 1 to 6 of 6